Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Varibar Honey
Overview
What is Varibar Honey?
VARIBAR® HONEY (Target Viscosity 3000 CPS)
Barium Sulfate Suspension (40% w/v, 29% w/w) is for oral administration.
Each 100 mL contains 40 g barium sulfate. Barium sulfate, due to its
high molecular density is opaque to x-rays and, therefore, acts as
a positive contrast agent for radiographic studies. The active ingredient
is barium sulfate and its structural formula is BaSO. Barium sulfate occurs as a fine, white, odorless, tasteless, bulky
powder which is free from grittiness. Its aqueous suspensions are
neutral to litmus. It is practically insoluble in water, solutions
of acids and alkalies, and organic solvents
Inactive Ingredients:
What does Varibar Honey look like?
What are the available doses of Varibar Honey?
Sorry No records found.
What should I talk to my health care provider before I take Varibar Honey?
Sorry No records found
How should I use Varibar Honey?
This
product is indicated for use in radiography of the esophagus, pharynx
and hypopharynx.
The dose of VARIBAR® HONEY to be administered will depend on the
degree and extent of contrast required in the area(s) under examination
and on the equipment and technique employed.
What interacts with Varibar Honey?
This product should not be used in patients with known or suspected gastrointestinal perforation; or hypersensitivity to barium sulfate or any components of this barium sulfate formulation.
What are the warnings of Varibar Honey?
Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
What are the precautions of Varibar Honey?
General
Diagnostic procedures
which involve the use of radiopaque contrast agents should be carried
out under the direction of personnel with the requisite training and
with a thorough knowledge of the particular procedure to be performed.
A history of bronchial asthma, atopy, as evidenced by hay fever and
eczema, or a previous reaction to a contrast agent, warrant special
attention. Caution should be exercised with the use of radiopaque
media in severely debilitated patients and in those with marked hypertension
or advanced cardiac disease.
Given that the contrast material is designed
for a procedure that is performed to document the presence and extent
of pathophysiology of the swallowing mechanism as well as to determine
appropriate remediation of such, aspiration of the barium sulfate
is an expected consequence for some patients. When this occurs, it
is recommended that the patient be assisted in attempts to expectorate
the aspirant. The study should be resumed if the clinician is prepared
to assess the patient’s response to specific interventions designed
to eliminate or minimize the recurrence of aspiration (postural changes,
sensory enhancements, swallowing maneuvers and/or dietary changes).
It is recommended that the study begin with the introduction of limited
amounts of material per swallow (3 mL or less).
After any barium study of the GI tract, it
is important to rehydrate the patient as quickly as possible to prevent
impaction of the bowel by barium sulfate. To prevent barium sulfate
impaction in the bowel, secondary to administration of large volumes
of this product (i.e. >120 mL) the use of mild laxatives such as milk
of magnesia or lactulose, following completion of the examination
may also be required.
Use with caution in patients with complete or nearly complete esophageal
or gastric obstruction.
Information for Patients
- Inform their physician if they are pregnant.
- Inform their physician if they are allergic to any drugs or food, or if they have had any prior reactions to barium sulfate products or other contrast agents used in x-ray procedures (see ).
- Inform their physician about any other medications they are currently taking.
Before administration of this product patients should be instructed to:
Drug Interactions
The presence of barium sulfate formulations in the GI tract may alter the absorption of therapeutic agents taken concomitantly. In order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.
Usage in Pregnancy
Radiation is known to cause harm to the unborn fetus exposed . Therefore, radiographic procedures should only be used when, in the judgement of the physician, their use is deemed essential to the welfare of the pregnant patient.
Nursing Mothers
Barium sulfate products may be used during lactation.
What are the side effects of Varibar Honey?
Adverse
reactions, such as nausea, vomiting, diarrhea and abdominal cramping,
accompanying the use of barium sulfate formulations are infrequent
and usually mild. Severe reactions (approximately 1 in 1,000,000)
and fatalities (approximately 1 in 10,000,000) have occurred. Procedural
complications are rare, but may include aspiration pneumonitis, barium
impaction, granuloma formation, intravasation, embolization and peritonitis
following intestinal perforation, vasovagal and syncopal episodes,
and fatalities. It is of the utmost importance to be completely prepared
to treat any such occurrence.
What should I look out for while using Varibar Honey?
This product
should not be used in patients with known or suspected gastrointestinal
perforation; or hypersensitivity to barium sulfate or any components
of this barium sulfate formulation.
Due to the increased likelihood of allergic reactions
in atopic patients, it is important that a complete history of known
and suspected allergies as well as allergic-like symptoms, e.g., rhinitis,
bronchial asthma, eczema and urticaria, must be obtained prior to
any medical procedure utilizing these products. A mild allergic reaction
would most likely include generalized pruritus, erythema or urticaria
(approximately 1 in 250,000). Such reactions will generally respond
to an antihistamine such as 50 mg of diphenhydramine or its equivalent.
In the rarer, more serious reactions (approximately 1 in 1,000,000)
laryngeal edema, bronchospasm or hypotension could develop. Severe
reactions which may require emergency measures are often characterized
by peripheral vasodilation, hypotension, reflex tachycardia, dyspnea,
agitation, confusion and cyanosis progressing to unconsciousness.
Treatment should be initiated immediately with 0.3 to 0.5 mL of 1:1000
epinephrine subcutaneously. If bronchospasm predominates, 0.25 to
0.50 grams of intravenous aminophylline should be given slowly. Appropriate
vasopressors might be required. Adrenocorticosteroids, even if given
intravenously, exert no significant effect on the acute allergic reactions
for a few hours. The administration of these agents should not be
regarded as emergency measures for the treatment of allergic reactions.
Apprehensive patients may develop weakness,
pallor, tinnitus, diaphoresis and bradycardia following the administration
of any diagnostic agent. Such reactions are usually non-allergic
in nature and are best treated by having the patient lie flat for
an additional 10 to 30 minutes under observation.
What might happen if I take too much Varibar Honey?
On rare occasions
following repeated administration, severe stomach cramps, nausea,
vomiting, diarrhea or constipation may occur. These are transitory
in nature and are not considered serious. Symptoms may be treated
according to currently accepted standards of medical care.
How should I store and handle Varibar Honey?
Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].Dispense in tight container as defined in the USP, with a child-resistant closure (as required).Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].Dispense in tight container as defined in the USP, with a child-resistant closure (as required).VARIBAR® HONEY is supplied in the following quantity: 250 mL bottle, Cat. No. D122, NDC 32909-122-07Manufactured by E-Z-EM Canada Inc.for E-Z-EM, Inc. a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 03/15 TX1746VARIBAR® HONEY is supplied in the following quantity: 250 mL bottle, Cat. No. D122, NDC 32909-122-07Manufactured by E-Z-EM Canada Inc.for E-Z-EM, Inc. a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 03/15 TX1746VARIBAR® HONEY is supplied in the following quantity: 250 mL bottle, Cat. No. D122, NDC 32909-122-07Manufactured by E-Z-EM Canada Inc.for E-Z-EM, Inc. a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 03/15 TX1746
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Barium sulfate,
due to its high molecular density is opaque to x-rays and, therefore,
acts as a positive contrast agent for radiographic studies. Barium
sulfate is biologically inert and, therefore, is not absorbed or metabolized
by the body, and is eliminated unchanged from the body.
Non-Clinical Toxicology
This product should not be used in patients with known or suspected gastrointestinal perforation; or hypersensitivity to barium sulfate or any components of this barium sulfate formulation.Due to the increased likelihood of allergic reactions in atopic patients, it is important that a complete history of known and suspected allergies as well as allergic-like symptoms, e.g., rhinitis, bronchial asthma, eczema and urticaria, must be obtained prior to any medical procedure utilizing these products. A mild allergic reaction would most likely include generalized pruritus, erythema or urticaria (approximately 1 in 250,000). Such reactions will generally respond to an antihistamine such as 50 mg of diphenhydramine or its equivalent. In the rarer, more serious reactions (approximately 1 in 1,000,000) laryngeal edema, bronchospasm or hypotension could develop. Severe reactions which may require emergency measures are often characterized by peripheral vasodilation, hypotension, reflex tachycardia, dyspnea, agitation, confusion and cyanosis progressing to unconsciousness. Treatment should be initiated immediately with 0.3 to 0.5 mL of 1:1000 epinephrine subcutaneously. If bronchospasm predominates, 0.25 to 0.50 grams of intravenous aminophylline should be given slowly. Appropriate vasopressors might be required. Adrenocorticosteroids, even if given intravenously, exert no significant effect on the acute allergic reactions for a few hours. The administration of these agents should not be regarded as emergency measures for the treatment of allergic reactions.
Apprehensive patients may develop weakness, pallor, tinnitus, diaphoresis and bradycardia following the administration of any diagnostic agent. Such reactions are usually non-allergic in nature and are best treated by having the patient lie flat for an additional 10 to 30 minutes under observation.
The presence of barium sulfate formulations in the GI tract may alter the absorption of therapeutic agents taken concomitantly. In order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.
Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease.
Given that the contrast material is designed for a procedure that is performed to document the presence and extent of pathophysiology of the swallowing mechanism as well as to determine appropriate remediation of such, aspiration of the barium sulfate is an expected consequence for some patients. When this occurs, it is recommended that the patient be assisted in attempts to expectorate the aspirant. The study should be resumed if the clinician is prepared to assess the patient’s response to specific interventions designed to eliminate or minimize the recurrence of aspiration (postural changes, sensory enhancements, swallowing maneuvers and/or dietary changes). It is recommended that the study begin with the introduction of limited amounts of material per swallow (3 mL or less).
After any barium study of the GI tract, it is important to rehydrate the patient as quickly as possible to prevent impaction of the bowel by barium sulfate. To prevent barium sulfate impaction in the bowel, secondary to administration of large volumes of this product (i.e. >120 mL) the use of mild laxatives such as milk of magnesia or lactulose, following completion of the examination may also be required.
Use with caution in patients with complete or nearly complete esophageal or gastric obstruction.
Adverse reactions, such as nausea, vomiting, diarrhea and abdominal cramping, accompanying the use of barium sulfate formulations are infrequent and usually mild. Severe reactions (approximately 1 in 1,000,000) and fatalities (approximately 1 in 10,000,000) have occurred. Procedural complications are rare, but may include aspiration pneumonitis, barium impaction, granuloma formation, intravasation, embolization and peritonitis following intestinal perforation, vasovagal and syncopal episodes, and fatalities. It is of the utmost importance to be completely prepared to treat any such occurrence.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).